JP2018538248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538248A5 JP2018538248A5 JP2018521294A JP2018521294A JP2018538248A5 JP 2018538248 A5 JP2018538248 A5 JP 2018538248A5 JP 2018521294 A JP2018521294 A JP 2018521294A JP 2018521294 A JP2018521294 A JP 2018521294A JP 2018538248 A5 JP2018538248 A5 JP 2018538248A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- compound according
- pharmaceutically acceptable
- ring
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Chemical group 0.000 description 8
- 229920006395 saturated elastomer Chemical group 0.000 description 8
- 229910052717 sulfur Chemical group 0.000 description 8
- 239000011593 sulfur Chemical group 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 5
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- -1 n-butylenyl Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020195185A JP7449843B2 (ja) | 2015-10-23 | 2020-11-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2024032219A JP2024073492A (ja) | 2015-10-23 | 2024-03-04 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2025139729A JP2025176049A (ja) | 2015-10-23 | 2025-08-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245553P | 2015-10-23 | 2015-10-23 | |
| US62/245,553 | 2015-10-23 | ||
| US201662336219P | 2016-05-13 | 2016-05-13 | |
| US62/336,219 | 2016-05-13 | ||
| PCT/US2016/058188 WO2017070518A1 (en) | 2015-10-23 | 2016-10-21 | Modulators of sestrin-gator2 interaction and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195185A Division JP7449843B2 (ja) | 2015-10-23 | 2020-11-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538248A JP2018538248A (ja) | 2018-12-27 |
| JP2018538248A5 true JP2018538248A5 (enExample) | 2019-11-28 |
| JP6800968B2 JP6800968B2 (ja) | 2020-12-16 |
Family
ID=58557891
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521294A Active JP6800968B2 (ja) | 2015-10-23 | 2016-10-21 | セストリン−ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2020195185A Active JP7449843B2 (ja) | 2015-10-23 | 2020-11-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2024032219A Withdrawn JP2024073492A (ja) | 2015-10-23 | 2024-03-04 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2025139729A Pending JP2025176049A (ja) | 2015-10-23 | 2025-08-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195185A Active JP7449843B2 (ja) | 2015-10-23 | 2020-11-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2024032219A Withdrawn JP2024073492A (ja) | 2015-10-23 | 2024-03-04 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
| JP2025139729A Pending JP2025176049A (ja) | 2015-10-23 | 2025-08-25 | セストリン－ｇａｔｏｒ２相互作用のモジュレーターおよびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10100066B2 (enExample) |
| EP (2) | EP3364958B1 (enExample) |
| JP (4) | JP6800968B2 (enExample) |
| KR (2) | KR102708250B1 (enExample) |
| CN (2) | CN121102186A (enExample) |
| AU (4) | AU2016342027B2 (enExample) |
| BR (1) | BR122021005850B1 (enExample) |
| CA (2) | CA3001703C (enExample) |
| CO (1) | CO2018005315A2 (enExample) |
| DK (1) | DK3364958T3 (enExample) |
| ES (1) | ES2941969T3 (enExample) |
| FI (1) | FI3364958T3 (enExample) |
| HR (1) | HRP20230331T1 (enExample) |
| HU (1) | HUE061437T2 (enExample) |
| IL (1) | IL258779B (enExample) |
| LT (1) | LT3364958T (enExample) |
| MX (2) | MX389001B (enExample) |
| PL (1) | PL3364958T3 (enExample) |
| PT (1) | PT3364958T (enExample) |
| RS (1) | RS64114B1 (enExample) |
| SG (1) | SG11201803099SA (enExample) |
| SI (1) | SI3364958T1 (enExample) |
| WO (1) | WO2017070518A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| ES2941969T3 (es) | 2015-10-23 | 2023-05-29 | Navitor Pharm Inc | Moduladores de la interacción de Sestrina-GATOR2 y sus usos |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| CN113164414A (zh) | 2018-10-24 | 2021-07-23 | 纳维托制药有限公司 | 多晶型化合物和其用途 |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| PL3873605T3 (pl) | 2018-10-30 | 2025-03-03 | Gilead Sciences, Inc. | Związki hamujące integrynę alfa4beta7 |
| EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
| CN111689993B (zh) * | 2019-03-11 | 2023-04-14 | 凯特立斯（深圳）科技有限公司 | 一种新的含硼类佐米药物关键中间体手性α-氨基硼酸酯的制备方法 |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| IL292612A (en) * | 2019-11-01 | 2022-07-01 | Navitor Pharm Inc | Treatment methods using mtorc1 modulator |
| CN112699498B (zh) * | 2021-03-23 | 2021-05-25 | 中国空气动力研究与发展中心计算空气动力研究所 | 基于归一化物理量间断特征的喷流模拟激波快速判别方法 |
| EP4234014A1 (en) * | 2022-02-28 | 2023-08-30 | Insusense ApS | Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases |
| KR102777583B1 (ko) | 2024-05-24 | 2025-03-07 | 충남대학교산학협력단 | 세스트린2를 포함하는 전립선 질환 예방 또는 치료용 조성물 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3452015A (en) * | 1967-07-12 | 1969-06-24 | Lilly Co Eli | Synthesis of beta,beta-alkyl pyrrolidines |
| US3567726A (en) * | 1968-12-18 | 1971-03-02 | Lilly Co Eli | Synthesis of beta,beta-di-alkyl pyrrolidines |
| US4110368A (en) | 1972-07-24 | 1978-08-29 | American Cyanamid Company | Hydro substituted prostanoic acids and esters |
| US4179574A (en) * | 1973-04-27 | 1979-12-18 | American Cyanamid Company | Novel 2-substituted-3,4-epoxycyclopentan-1-ones, 2-substituted-3,4-epoxycyclopentan-1-ols, and various 2-substituted-cyclo-pentenones |
| US4346110A (en) | 1981-06-01 | 1982-08-24 | Merrell Toraude Et Compagnie | Method for treating depression |
| JPS61149964A (ja) | 1984-12-25 | 1986-07-08 | Canon Inc | 電子写真感光体 |
| US4670196A (en) | 1985-09-05 | 1987-06-02 | Norton Company | Tower packing element |
| DE3765646D1 (de) | 1986-01-24 | 1990-11-29 | Toray Industries | 2,5,6,7-tetranor-4,8-inter-m-phenylen-pgi2-derivate. |
| GB8827885D0 (en) | 1988-11-30 | 1989-01-05 | Wellcome Found | Novel heterocyclic pesticidal compounds |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| DE19623142A1 (de) | 1996-06-10 | 1997-12-11 | Huels Chemische Werke Ag | Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung |
| PL331854A1 (en) | 1996-08-28 | 1999-08-16 | Procter & Gamble | Phosphinamides as inhibitors of metaloprotease matrix |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US6458781B1 (en) * | 1998-04-27 | 2002-10-01 | David Thomas Connor | Substituted diarylalkyl amides as calcium channel antagonists |
| AU6342099A (en) | 1998-11-04 | 2000-05-22 | Montell Technology Company B.V. | Components and catalysts for the polymerization of olefins |
| US6329546B1 (en) | 1999-01-12 | 2001-12-11 | Laboratory Of Molecular Biophotonics | Caged amino acids |
| US20030203900A1 (en) * | 1999-05-18 | 2003-10-30 | Martin Quibell | Cysteine protease inhibitors |
| KR100694735B1 (ko) * | 1999-06-10 | 2007-03-14 | 워너-램버트 캄파니 엘엘씨 | 일치환 및 이치환된 3-프로필 감마-아미노부티르산 |
| CZ303875B6 (cs) | 1999-12-10 | 2013-06-05 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem |
| US7300775B2 (en) * | 1999-12-29 | 2007-11-27 | Verenium Corporation | Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP5076257B2 (ja) * | 2001-02-01 | 2012-11-21 | 旭硝子株式会社 | 撥水性組成物、表面処理された基材、その製造方法および輸送機器用物品 |
| US7071189B2 (en) | 2001-04-27 | 2006-07-04 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| CN1674929B (zh) | 2002-08-14 | 2013-07-17 | 赛伦斯治疗公司 | 蛋白激酶Nβ的应用 |
| US6787664B2 (en) * | 2002-09-17 | 2004-09-07 | Warner-Lambert Company Llc | Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| AU2004242928B2 (en) | 2003-05-30 | 2011-03-10 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| EP2371835A1 (en) | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| US20070212428A1 (en) | 2004-06-04 | 2007-09-13 | Mood Management Sciences, Inc. | Methods and compositions for treating mood disorder |
| DE102004053407A1 (de) * | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Acylierte Nonadepsipeptide II |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| BRPI0607140A2 (pt) * | 2005-02-18 | 2009-08-11 | Innodia Inc | composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios |
| DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007044729A2 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| KR101391900B1 (ko) | 2005-12-13 | 2014-05-02 | 인사이트 코포레이션 | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘 |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| UA95799C2 (en) | 2006-04-26 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Pharmaceutical compounds |
| AU2007288226A1 (en) | 2006-08-21 | 2008-02-28 | Prexa Pharmaceuticals, Inc. | Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
| EP2526934B1 (en) | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CN101616588B (zh) | 2006-09-25 | 2013-09-25 | 沃克哈特研究中心 | 取代的哌啶子基苯基噁唑烷酮 |
| TWI397418B (zh) | 2006-10-10 | 2013-06-01 | Otsuka Pharma Co Ltd | 抗憂鬱劑 |
| KR20090064458A (ko) | 2006-10-20 | 2009-06-18 | 머크 앤드 캄파니 인코포레이티드 | 봄베신 수용체 아형-3 조절제로서의 치환된 이미다졸 |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| EP2193119B1 (en) * | 2007-08-27 | 2014-01-01 | Abbvie Deutschland GmbH & Co. KG | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| MX2010010012A (es) | 2008-03-11 | 2010-10-20 | Incyte Corp | Derivados de azetidina y ciclobutano como inhibidores de jak. |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| EP2350053B1 (en) | 2008-10-17 | 2013-12-11 | Whitehead Institute For Biomedical Research | Modulators of MTOR Complexes |
| US8785674B2 (en) * | 2009-06-19 | 2014-07-22 | Lek Pharmaceuticals D.D. | Process for hydrogenation of halogenoalkenes without dehalogenation |
| US20120219596A1 (en) | 2009-07-30 | 2012-08-30 | Wendelin Stark | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| MX2012008533A (es) * | 2010-01-29 | 2012-08-31 | Boehringer Ingelheim Int | Naftiridinas sustituidas y su uso como inhibidores de syk quinasa. |
| PH12012502572A1 (en) | 2010-06-30 | 2022-03-30 | Fujifilm Corp | Novel nicotinamide derivative or salt thereof |
| CN102464701B (zh) * | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| ES2545110T3 (es) * | 2010-12-10 | 2015-09-08 | Rottapharm Biotech S.R.L. | Derivados de piridinamida como antagonistas del receptor EP4 |
| EP2678037B1 (en) | 2011-02-25 | 2014-12-03 | Lonza Ltd | Branched linker for protein drug conjugates |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| WO2013142229A1 (en) * | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| WO2014022879A1 (en) | 2012-08-06 | 2014-02-13 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of mtor pathway related diseases |
| US20160002159A1 (en) * | 2013-02-13 | 2016-01-07 | Neal ZONDLO | Perfluoro-tert-butyl hydroxyproline |
| US9650376B2 (en) | 2013-03-15 | 2017-05-16 | Knopp Biosciences Llc | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators |
| WO2014201111A1 (en) | 2013-06-14 | 2014-12-18 | The Brigham And Women's Hospital, Inc. | Treatment of mtor hyperactive related diseases and disorders |
| EP3191116B1 (en) | 2014-09-12 | 2020-11-25 | The Whitehead Institute for Biomedical Research | Methods of identifying modulators of sestrin-gator2 interaction and use of same to modulate mtorc1 |
| ES2941969T3 (es) | 2015-10-23 | 2023-05-29 | Navitor Pharm Inc | Moduladores de la interacción de Sestrina-GATOR2 y sus usos |
| US20180327364A1 (en) | 2015-11-13 | 2018-11-15 | Brandeis University | Mtor inhibitors and methods of use thereof |
| CN109789316B (zh) | 2016-04-21 | 2022-09-27 | 贝勒医学院 | 用于治疗溶酶体贮积症和以溶酶体功能障碍为特征的病症的组合物和方法 |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| CA3090258A1 (en) | 2018-02-08 | 2019-08-15 | Ovid Therapeutics Inc. | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus and acute sensorineural hearing loss |
| CN113164414A (zh) | 2018-10-24 | 2021-07-23 | 纳维托制药有限公司 | 多晶型化合物和其用途 |
| US10926803B2 (en) | 2019-07-17 | 2021-02-23 | GM Global Technology Operations LLC | Four rail front crush structure with load dissemination into eight element support structure |
| JP6689441B1 (ja) | 2019-11-01 | 2020-04-28 | エヌ・ティ・ティ・コミュニケーションズ株式会社 | 電子マネー管理システムおよび電子マネー管理方法 |
| IL292612A (en) | 2019-11-01 | 2022-07-01 | Navitor Pharm Inc | Treatment methods using mtorc1 modulator |
-
2016
- 2016-10-21 ES ES16858326T patent/ES2941969T3/es active Active
- 2016-10-21 CN CN202511264584.8A patent/CN121102186A/zh active Pending
- 2016-10-21 CA CA3001703A patent/CA3001703C/en active Active
- 2016-10-21 PL PL16858326.8T patent/PL3364958T3/pl unknown
- 2016-10-21 MX MX2018004674A patent/MX389001B/es unknown
- 2016-10-21 WO PCT/US2016/058188 patent/WO2017070518A1/en not_active Ceased
- 2016-10-21 CN CN201680069916.XA patent/CN108289866B/zh active Active
- 2016-10-21 HR HRP20230331TT patent/HRP20230331T1/hr unknown
- 2016-10-21 CA CA3234750A patent/CA3234750A1/en active Pending
- 2016-10-21 RS RS20230265A patent/RS64114B1/sr unknown
- 2016-10-21 EP EP16858326.8A patent/EP3364958B1/en active Active
- 2016-10-21 EP EP22186093.5A patent/EP4112611A3/en active Pending
- 2016-10-21 US US15/331,362 patent/US10100066B2/en active Active
- 2016-10-21 FI FIEP16858326.8T patent/FI3364958T3/fi active
- 2016-10-21 KR KR1020187011517A patent/KR102708250B1/ko active Active
- 2016-10-21 AU AU2016342027A patent/AU2016342027B2/en active Active
- 2016-10-21 LT LTEPPCT/US2016/058188T patent/LT3364958T/lt unknown
- 2016-10-21 SI SI201631682T patent/SI3364958T1/sl unknown
- 2016-10-21 PT PT168583268T patent/PT3364958T/pt unknown
- 2016-10-21 HU HUE16858326A patent/HUE061437T2/hu unknown
- 2016-10-21 DK DK16858326.8T patent/DK3364958T3/da active
- 2016-10-21 BR BR122021005850-4A patent/BR122021005850B1/pt active IP Right Grant
- 2016-10-21 JP JP2018521294A patent/JP6800968B2/ja active Active
- 2016-10-21 SG SG11201803099SA patent/SG11201803099SA/en unknown
- 2016-10-21 KR KR1020247030702A patent/KR20240144424A/ko active Pending
-
2018
- 2018-04-16 MX MX2022000053A patent/MX2022000053A/es unknown
- 2018-04-17 IL IL258779A patent/IL258779B/en unknown
- 2018-05-09 US US15/974,734 patent/US10414782B2/en active Active
- 2018-05-21 CO CONC2018/0005315A patent/CO2018005315A2/es unknown
-
2019
- 2019-07-18 US US16/515,788 patent/US10752644B2/en active Active
-
2020
- 2020-07-29 US US16/941,821 patent/US11325924B2/en active Active
- 2020-11-25 JP JP2020195185A patent/JP7449843B2/ja active Active
-
2021
- 2021-08-11 AU AU2021215177A patent/AU2021215177B2/en active Active
-
2022
- 2022-03-25 US US17/704,892 patent/US12378263B2/en active Active
-
2023
- 2023-12-12 AU AU2023282205A patent/AU2023282205A1/en not_active Abandoned
-
2024
- 2024-03-04 JP JP2024032219A patent/JP2024073492A/ja not_active Withdrawn
-
2025
- 2025-08-25 JP JP2025139729A patent/JP2025176049A/ja active Pending
- 2025-10-14 AU AU2025252521A patent/AU2025252521A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538248A5 (enExample) | ||
| JP2020517707A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2010528021A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| RU2016152470A (ru) | Применение замещенных оксадиазолов для борьбы с фитопатогенными грибами | |
| JP2020503249A5 (enExample) | ||
| JP2017536369A5 (enExample) | ||
| JP2012508252A5 (enExample) | ||
| JP2018524333A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2015509110A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| RU2017144495A (ru) | Противогельминтные депсипептидные соединения | |
| JP2016534059A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2013505946A5 (enExample) | ||
| JP2019510794A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| JP2019527724A5 (enExample) |